Organon's Stock Plummets After Sales Forecast Cut

episode

Business News Today | 2 Min News | The Daily News Now! not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

More from Business News Today | 2 Min News | The Daily News Now!

Japanese Capsule Hotels: Budget Solution for London Hybrid Workers 1 min · 20 Dec 2025

Russia's War Economy: Sustainable or Unsustainable? 2 min · 20 Dec 2025

All episodes from Business News Today | 2 Min News | The Daily News Now! →

Report any issue

Source

Recorded11 Nov 2025

Publisherfeeds.acast.com ↗

Handlerec:2197363

Show notes

Organons stock plummeted by nearly 3% following a revised sales forecast, disappointing market analysts and leading to lowered price targets. Despite better-than-expected earnings, challenges with Nexplanon and respiratory products have investors concerned. The stock has been volatile, with 21 movements greater than 5% in the past year, and is now trading at around $7.63, a stark contrast to its $16.41 52-week high. An initial $1000 investment in May 2021 would now be worth approximately $229.41.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.